Core Viewpoint - The successful implementation of the EVO+ICL(V5) surgery at Shanghai Aier Eye Hospital marks a significant advancement in vision correction technology, particularly for individuals with high demands for night vision quality, offering a revolutionary "day and night high-definition" experience [1][8]. Group 1: Technology and Innovation - The EVO+ICL(V5) technology features an expanded optical zone design that effectively reduces night glare and halos, making it particularly suitable for individuals with high night vision requirements [2][4]. - The new ICL technology can correct a wide range of vision issues, accommodating myopia from 50 to 1400 degrees and astigmatism up to 600 degrees, while being reversible and not requiring corneal cutting [2][4]. - The EVO+ICL(V5) lens has an optical zone that expands to 7.6mm, significantly improving night vision by better covering the dark pupil [4]. Group 2: Material and Manufacturing - The lens is made from a unique Collamer material, which offers high biocompatibility, flexibility, effective UV blockage, and excellent long-term safety, ensuring a stable and lasting high-definition visual experience [5]. - The manufacturing process utilizes Swiss precision engineering, focusing on meticulous detail and continuous innovation to provide cutting-edge visual quality [6]. Group 3: Clinical Validation and Experience - The ICL technology has been validated through over 30 years of clinical practice, with more than 3 million lenses implanted globally across 75 countries, highlighting its reliability and acceptance among both doctors and patients [7]. - The successful surgery at Shanghai Aier Eye Hospital reflects the institution's strong technical capabilities, supported by a history of completing 550,000 ICL surgeries by 2025 and extensive experience in correcting high myopia and complex refractive errors [8][9]. Group 4: Future Directions - The hospital aims to continue introducing and applying globally leading technologies to meet the diverse and refined visual needs of urban residents, emphasizing a patient-centered approach in providing safe, precise, and clear vision correction solutions [9].

Group 1 - The company, Aier Eye Hospital Group, focuses on ophthalmology and is committed to keeping up with advancements in interdisciplinary fields [1]

Group 1 - The company, Chaoyujian Ophthalmology (02219), announced that the Hong Kong Stock Exchange has granted a new exemption effective January 6, 2026 [1] - Mr. Zhang Guangdi has been appointed as a joint company secretary for a term of three years, starting from January 7, 2026 [1] - Following this change, Mr. Luo Weijian will continue to serve as another joint company secretary [1]

Core Insights - The launch of the EVO+ICL(V5) project at Shenzhen Hima Lin Shun Chao Eye Hospital marks a significant advancement in refractive surgery technology in the Greater Bay Area, allowing local patients access to cutting-edge vision correction techniques [1][2] Group 1: Project Launch and Significance - The Shenzhen Hima Eye Hospital initiated the EVO+ICL(V5) project on January 7, 2023, following the first surgery on January 5, 2023, establishing a clinical application cooperation center and certifying surgeons [1][2] - The project is supported by strategic partnerships with leading global medical manufacturers, emphasizing the importance of international technology sharing for domestic healthcare [2][3] Group 2: Clinical Achievements and Future Plans - Shenzhen Hima Eye Hospital has performed over 10,000 ICL surgeries, showcasing its comprehensive refractive correction system and readiness for the new technology [3] - The hospital aims to implement strict operational standards and quality control systems to ensure the safe and precise application of the EVO+ICL(V5) technology [3] Group 3: Patient Experience and Technology Advantages - The first patient to undergo the EVO+ICL(V5) surgery reported significant improvements in vision quality, achieving a vision score of over 1.0 after the procedure [4] - The V5 technology offers four key advantages: larger optical zone design, improved night vision sensitivity, Swiss precision manufacturing, and over 30 years of clinical validation with more than 3 million implants globally [4]

Group 1 - The core viewpoint of the article is that Aier Eye Hospital (300015) has successfully achieved mass production of its "Little Green Sprout" series products, which are reported to have effective myopia prevention capabilities [1] Group 2 - The "Little Green Sprout" series products are designed to address myopia, indicating a focus on eye health and preventive care in the ophthalmology sector [1] - The announcement was made in response to investor inquiries on the company's interactive platform, highlighting the company's engagement with its investors [1]

证券日报网讯1月7日，爱尔眼科（300015）在互动平台回答投资者提问时表示，爱尔网络覆盖中国广大 城乡县域，截至2025年6月30日，公司境内医院355家，门诊部240家，详情请查阅爱尔眼科官网。 ...

格隆汇1月7日丨爱尔眼科(300015.SZ)在投资者互动平台表示，"小青葵"系列产品已实现量产。 ...

Core Viewpoint - The inclusion of the targeted drug Teprotumumab in the national medical insurance directory starting January 1, 2026, marks a significant advancement in the treatment of Thyroid Eye Disease (TED), providing financial relief for patients who previously faced high treatment costs [1][3]. Group 1: Drug and Treatment Details - Teprotumumab is the first domestically approved targeted therapy for TED, significantly reducing treatment costs from approximately 3 million yuan per course to under 6000 yuan per injection after insurance reimbursement [3][5]. - Patients like Ms. Li, who previously struggled with traditional treatments, can now access this innovative therapy, with personal costs reduced to 1909.12 yuan per injection after insurance [1][3]. Group 2: Clinical Impact and Patient Management - Early diagnosis and treatment are crucial for managing TED symptoms, which include eye bulging and vision impairment, potentially leading to severe complications [4]. - The Dongguan Aier Eye Hospital has established a specialized clinic for TED, offering comprehensive management from prevention to rehabilitation, ensuring tailored treatment plans for patients [5]. Group 3: Economic and Accessibility Implications - The inclusion of Teprotumumab in the insurance scheme signifies a new era of accessibility for TED treatment, allowing more patients to benefit from effective and safe targeted therapies [5]. - The policy change is expected to alleviate the financial burden on patients, enabling timely access to necessary treatments [5].

Core Viewpoint - The launch of the EVO ICL (V5) crystal implantation surgery in Gansu marks the introduction of a cutting-edge myopia correction technology, allowing local patients to access advanced treatment without traveling abroad [2][3]. Group 1: Technology and Innovation - The EVO ICL V5 crystal features a key advancement with an optical zone diameter increased from 5.8 mm to 6.1 mm, significantly enhancing night vision quality for patients, especially those with larger pupils, and reducing glare and halos [2]. - The V5 crystal improves the correction precision for moderate to low myopia to a range of 25 degrees, promoting personalized treatment options [2]. - The crystal has high biocompatibility and UV-blocking capabilities, having undergone over 30 years of clinical validation globally, making it a reliable surgical choice due to its non-cutting, safe, and reversible nature [2]. Group 2: Clinical Implementation and Recognition - The V5 technology's regular implementation in Lanzhou signifies its official approval by national authorities, allowing patients in Gansu and the northwest region to benefit from this advanced technology locally [3]. - A plaque ceremony was held to establish the "EVO ICL V5 Crystal Gansu Clinical Application Popularization Alliance," highlighting the collaboration between STAAR company and local hospitals, along with the certification of the first surgical expert in Gansu [3][5]. Group 3: Safety and Patient Experience - The V5 crystal maintains the safety foundation of its predecessor, with innovations primarily in optical design, supported by over 40 precise preoperative examinations to ensure safety and effectiveness [5]. - Different myopia correction techniques cater to various needs, with the EVO ICL (V5) particularly suited for patients with high myopia (over 600 degrees) and those requiring enhanced night vision, such as drivers [5]. - Patient testimonials shared during the event highlighted improvements in night vision and overall quality of life, resonating with the audience [5]. Group 4: Future Directions - The Lanzhou Eye Hospital plans to continue introducing global innovative technologies, ensuring a comprehensive range of surgical options and strict quality control to provide safer, more precise, and personalized visual quality enhancement solutions for patients in the northwest region [5].

2026年1月5日，博士伦公司事业部总监Garry Lau、国药瑞德医疗器材有限公司总经理朱鼎宏一行到访 华厦眼科。集团领导陈凤国携相关部门负责人热情接待，围绕眼病手术领域的技术革新、临床应用与服 务质量提升，展开深度座谈交流。此次战略对话旨在进一步深化战略合作，共同探索眼病手术诊疗新模 式，推动眼病服务向更高品质、更精准、更可及的方向迈进。 共叙合作情谊，共话发展愿景 集团领导陈凤国对博士伦与国药瑞德一行的到访表示热烈欢迎。他指出，"一切以病人为中心"是华厦眼 科始终不变的服务宗旨。"十四五"期间，我国CSR(每百万人白内障手术例数)不断提高，但较发达国家 仍有较大差距。从长远看，提升眼病手术的普及率与技术水平仍是行业重要使命。 他强调，提升眼病手术诊疗服务质量是双方共同的责任与追求，期待通过更全面的资源整合，探索高品 质眼病服务新路径，造福更多眼疾患者。 博士伦事业部总监Garry Lau深情回顾，博士伦与华厦眼科是22载的"老朋友"，彼此的信任早已根深叶 茂。他表示，华厦眼科拥有顶尖的专家团队、强大的临床实力与广泛的基层医疗网络覆盖能力，是国内 眼科医疗领域的佼佼者，也是博士伦创新产品的优先合作伙伴。 ...